Peptide receptor radionuclide therapy for neuroendocrine tumours: standardized and randomized, or personalized?

被引：0
作者：
Michael S. Hofman
Rodney J. Hicks
机构：
[1] Centre for Cancer Imaging,Molecular Imaging
[2] Peter MacCallum Cancer Centre,Department of Medicine
[3] The University of Melbourne,Centre for Cancer Imaging
[4] Peter MacCallum Cancer Centre,undefined
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2014年 / 41卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：211 / 213
页数：2
相关论文
共 50 条
[41]   Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial [J].
Michela Del Prete ;
François-Alexandre Buteau ;
Frédéric Arsenault ;
Nassim Saighi ;
Louis-Olivier Bouchard ;
Alexis Beaulieu ;
Jean-Mathieu Beauregard .
European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 :728-742
[42]   Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial [J].
Del Prete, Michela ;
Buteau, Francois-Alexandre ;
Arsenault, Frederic ;
Saighi, Nassim ;
Bouchard, Louis-Olivier ;
Beaulieu, Alexis ;
Beauregard, Jean-Mathieu .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (03) :728-742
[43]   Can peptide receptor radionuclide therapy be safely applied in florid bone metastases of gastroenteropancreatic neuroendocrine tumours? [J].
Sabet, A. ;
Yong-Hing, C. ;
Ezziddin, K. ;
Ahmadzadehfar, H. ;
Guhlke, S. ;
Gruenwald, F. ;
Biersack, H. ;
Ezziddin, S. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 :S332-S332
[44]   Retreatment with peptide receptor radionuclide therapy in patients with progressing neuroendocrine tumours: efficacy and prognostic factors for response [J].
Vaughan, Emily ;
Machta, Joseph ;
Walker, Martin ;
Toumpanakis, Christos ;
Caplin, Martyn ;
Navalkissoor, Shaunak .
BRITISH JOURNAL OF RADIOLOGY, 2018, 91 (1091)
[45]   The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours [J].
Zaknun, John J. ;
Bodei, L. ;
Mueller-Brand, J. ;
Pavel, M. E. ;
Baum, R. P. ;
Hoersch, D. ;
O'Dorisio, M. S. ;
O'Dorisiol, T. M. ;
Howe, J. R. ;
Cremonesi, M. ;
Kwekkeboom, D. J. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (05) :800-816
[46]   The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours [J].
John J. Zaknun ;
L. Bodei ;
J. Mueller-Brand ;
M. E. Pavel ;
R. P. Baum ;
D. Hörsch ;
M. S. O’Dorisio ;
T. M. O’Dorisiol ;
J. R. Howe ;
M. Cremonesi ;
D. J. Kwekkeboom .
European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40 :800-816
[47]   Peptide Receptor Radionuclide Therapy as First Line Systemic Treatment in Advanced Inoperable/Metastatic Neuroendocrine Tumours [J].
Satapathy, Swayamjeet ;
Sood, Ashwani ;
Sood, Apurva ;
Mittal, Bhagwant .
JOURNAL OF NUCLEAR MEDICINE, 2020, 61
[48]   The College of Nuclear Physicians of South Africa Practice Guidelines on Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumours [J].
Lawal, I ;
Louw, L. ;
Warwick, J. ;
Nyakale, N. ;
Steyn, R. ;
Lengana, T. ;
Ellmann, A. ;
Kotze, T. ;
Vangu, M. ;
Vorster, M. ;
Sathekge, M. .
SOUTH AFRICAN JOURNAL OF SURGERY, 2018, 56 (03) :55-64
[49]   Peptide receptor radionuclide therapy proves to be safe and immediately efficient in elderly patients with symptomatic neuroendocrine tumours [J].
Duan, H. ;
Dolliner, P. ;
Dobrozemsky, G. ;
Raderer, M. ;
Hoffmann, M. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 :S199-S200
[50]   Can peptide receptor radionuclide therapy be safely applied in florid bone metastases of gastroenteropancreatic neuroendocrine tumours? [J].
Sabet, Amir ;
Yong-Hing, Charlotte ;
Ezziddin, Khaled ;
Ahmadzadehfar, Hojjat ;
Guhlke, Stefan ;
Gruenwald, Frank ;
Biersack, Hans Juergen ;
Ezziddin, Samer .
JOURNAL OF NUCLEAR MEDICINE, 2012, 53
12345